: Development, Optimization, and Scale up of a Human Growth Hormone PEGylation Process

Monday, November 9, 2009: 4:15 PM
Bayou B (Gaylord Opryland Hotel)

John J. Buckley, Global Biologics, Pfizer Global R&D, Chesterfield, MO
Gopinath V. Annathur, Global Biologics, Pfizer Global R&D, Chesterfield, MO
Sa V. Ho, Global Biologics, Pfizer Global R&D, Chesterfield, MO
Rory Finn, Pfizer Global R&D, Pfizer Global R&D, Chesterfield, MO
Brandi Osborne, Global Biologics, Pfizer Global R&D, Chesterfield, MO
Denis Boyle, Global Biologics, Pfizer Global R&D, Chesterfield, MO
Kristen Thomas, Global Biologics, Pfizer Global R&D, Chesterfield, MO
Althea Micklewright, Global Biologics, Pfizer Global R&D, Chesterfield, MO

A history of the development and scale up of the process for PEGylation of human growth hormone is described. The development of the PEGylation procedure from initial discovery process through commercial scale up for production of clinical supply materials is described. Optimization of process chemistry, including reagent selection and condition optimization are described. Development and application of a kinetic model for the reaction and its application to prediction of optimum process conditions is described.
Extended Abstract: File Not Uploaded
See more of this Session: Advances in API Process Development
See more of this Group/Topical: Food, Pharmaceutical & Bioengineering Division